Symptoms of Allergic Rhinitis Result in Sleep Disturbances and Emotional Burdens for Nasal Allergy Patients
HORSHAM, Pa., May 10, 2011 /PRNewswire/ — Teva Respiratory today announced results from the recently completed Nasal Allergy Survey Assessing Limitations (NASL) 2010, which found patients with allergic rhinitis (AR) who had nasal symptoms were more likely to experience sleep disturbances, including difficulty getting to sleep and/or waking up during the night. Lack of a good night’s sleep can significantly impact a person’s quality of life. For people living with nasal allergies in the United States, these symptoms, including post-nasal drip, repeated sneezing, nasal congestion and headache, are reportedly at their worst during the spring months, specifically April and May.
Results from NASL 2010 suggest the fatigue nasal allergy patients are experiencing may be related to sleep disruption caused by the common symptoms associated with AR. Lack of adequate sleep and increased tiredness may also lead to patients feeling ‘irritable’ and ‘miserable,’ which can contribute to other emotional and mood effects like anxiety and depression. When nasal symptoms are at their worst, patients find it difficult to get a good night’s sleep, which can negatively impact their work performance by reducing productivity, resulting in both social and economic costs.
“The negative impact that allergic rhinitis symptoms can have on a patient’s quality of sleep is considerable, as it not only affects them physically, but also emotionally,” said Gary Gross, M.D. FAAAAI, Dallas Allergy & Asthma Center, Dallas, Texas. “As allergy season is upon us, it’s important for patients suffering from allergic rhinitis symptoms, like post-nasal drip, to understand how these symptoms can negatively affect their quality of life.”
Teva Respiratory recently presented findings from NASL 2010 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Francisco. According to these results, less than 20 percent of patients surveyed felt their nasal allergy symptoms were completely controlled. While the vast majority of respiratory specialists and primary care providers surveyed identified intranasal corticosteroid sprays as their preferred treatment for nasal allergies, currently the only intranasal corticosteroids available for the treatment of AR are products with an aqueous or “wet” spray. Patients reported being less satisfied with current nasal sprays when they experienced discomfort from the spray or when they felt the medication drip down the back of their throat. Healthcare providers and specialists also reported patient dissatisfaction with current nasal sprays due to the bothersome side effects associated with these treatments.
“NASL 2010 shows us that patients continue to experience the symptoms of AR, despite currently available treatment options, which impacts their quality of life as these ‘wet’ sprays often cause bothersome side effects,” continued Dr. Gross. “These results reinforce the need for alternative treatments to help alleviate these symptoms and overall disease burden of allergic rhinitis.”
During National Asthma and Allergy Awareness Month, several advocacy and government organizations across the nation will join together to increase public awareness of allergic conditions, including AR. Although AR is a widespread condition affecting an estimated 60 million people in the United States, current perspectives relating to the common symptoms and overall disease burden have been lacking. NASL 2010 provides a recent assessment of patient and healthcare provider perspectives concerning AR. To learn more, visit www.naslsurvey.com and download the full executive summary of results.
About The Nasal Allergy Survey Assessing Limitations (NASL) 2010
The Nasal Allergy Survey Assessing Limitations (NASL) provides a current assessment of patient and healthcare provider perspectives concerning allergic rhinitis. A national sample of 400 people aged 18 and older, who had been diagnosed with allergic rhinitis, nasal allergies or hay fever, and who had experienced nasal allergy symptoms or taken medication for their condition in the past 12 months, were interviewed as part of this study. This national sample of adults with current nasal allergies was interviewed by telephone during May and June 2010 about their condition and treatment. In order to determine the burden of disease of allergic rhinitis, a parallel telephone survey was conducted among a national probability sample of 522 adults sampled by random digit dialing. This survey of the general adult population of the U.S. yielded a subsample of 400 persons aged 18 and older who did not have current nasal allergies. The comparison of the two samples of adults with and without nasal allergies provides a new measure of the impact of nasal allergies on the health and lifestyle of patients.
A third parallel survey was conducted among 250 healthcare practitioners who see patients with nasal allergies. The healthcare practitioner sample includes a national sample of 200 physicians in direct patient care in outpatient settings in the U.S., including 100 in adult primary care specialties (family practice and general internal medicine) and 100 specialists (allergy and otolaryngology). In addition, a national sample of 50 nurse practitioners and physician assistants were interviewed as part of the study.
About Allergic Rhinitis
Allergic rhinitis (AR) is a chronic inflammatory disease characterized by symptoms such as sneezing, nasal itch, rhinorrhea, and nasal congestion. Based on the available evidence, intranasal corticosteroids are the most effective treatment options for patients with AR. Morbidity associated with AR can be significant. Effective treatment of AR may improve asthma control when both diseases coexist.
In the U.S., the prevalence of AR has increased during the past three decades; it is recently estimated at 20% in the general adult population and closer to 40% in children. Of the estimated 60 million Americans affected with AR, approximately 20% have SAR, 40% have PAR, and 40% have a combination of the two (i.e., PAR with seasonal exacerbation) depending on the allergen sensitivity. Because of its prevalence and health effect, AR is associated with considerable direct and indirect costs. An estimate of $11.2 billion in healthcare costs, 12 million physician office visits, 2 million days of school absences and 3.5 million lost work days per year are attributed to AR. In addition, the presence of co-morbidities such as asthma and sinusitis further increase AR-related treatment costs.
About Teva Respiratory
Teva Respiratory is the U.S.-based respiratory subsidiary of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA). Teva Pharmaceutical Industries Ltd., headquartered in Israel, is a leading global pharmaceutical company and the world’s largest generic drug maker. Teva has a global product portfolio of more than 1,250 molecules and a direct presence in approximately 60 countries. The company is committed to increasing access to high quality healthcare by developing, manufacturing and marketing generic products; innovative and specialty pharmaceuticals; and active pharmaceutical ingredients.
Teva’s Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
Teva’s Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: The statements, analyses and other information contained herein relating to the proposed acquisition and its effects on financial and operating performance, including estimates for growth, anticipated positions in certain markets and shares in such markets, the markets for Teva and Cephalon’s products, trends in Teva and Cephalon’s operating and financial results, the future development and operation of Teva and Cephalon’s business, and the contingencies and uncertainties to which Teva and Cephalon may be subject, as well as other statements including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “will,” “should,” “may” and other similar expressions, are “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. Such statements are made based upon management’s current expectations and beliefs concerning future events and their potential effects on the company and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results may differ materially from the results anticipated in these forward-looking statements. Important factors that could cause or contribute to such differences include whether and when the proposed acquisition will be consummated and the terms of any conditions imposed in connection with such closing, our ability to rapidly integrate Cephalon’s operations and achieve expected synergies, diversion of management time on merger-related issues, our ability to predict future market conditions with accuracy, our ability to develop and commercialize additional pharmaceutical products, competition from the introduction of competing generic equivalents and due to increased governmental pricing pressures, the effects of competition on sales of our innovative products, especially CopaxoneÃ‚® (including competition from innovative orally-administered alternatives as well as from potential generic equivalents), potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of NeurontinÃ‚®, LotrelÃ‚® and ProtonixÃ‚®, the extent to which we may obtain U.S. market exclusivity for certain of our new generic products, the extent to which any manufacturing or quality control problems damage our reputation for high quality production and require costly remediation, , our ability to identify, consummate and successfully integrate acquisitions (including the acquisition of Cephalon), our ability to achieve expected results through our innovative R&D efforts, dependence on the effectiveness of our patents and other protections for innovative products, intense competition in our specialty pharmaceutical businesses, uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, our potential exposure to product liability claims to the extent not covered by insurance, any failures to comply with the complex Medicare and Medicaid reporting and payment obligations, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement, adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, the impact of continuing consolidation of our distributors and customers, the difficulty of complying with U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority requirements, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities resulting from challenges to our intercompany arrangements, the termination or expiration of governmental programs or tax benefits, any failure to retain key personnel or to attract additional executive and managerial talent, environmental risks and other factors that are discussed in our filings with the SEC.
SOURCE Teva Respiratory